Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Small Pharma Inc V.DMT

Healthcare
Small Pharma Inc. is a biotechnology company focused on short-duration psychedelic therapies for mental health conditions. The Company is focused on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions that are scalable, commercially differentiated, and conveniently dosed, with the goal of addressing key unmet needs in the treatment of... see more

Recent & Breaking News (TSXV:DMT)

Small Pharma to Participate in Upcoming September Investor Conferences

GlobeNewswire September 8, 2022

Small Pharma (TSXV:DMT) announces NCIB

Trevor Abes  August 18, 2022

Small Pharma Announces TSXV Approval of Normal Course Issuer Bid

GlobeNewswire August 18, 2022

Small Pharma (TSXV:DMT) receives approval for DMT-assisted psychotherapy & SSRI drug study

Jonathon Brown August 15, 2022

Small Pharma Receives Approval for DMT-Assisted Psychotherapy and SSRI Drug Interaction Study

GlobeNewswire August 15, 2022

Canadian Patent Grant Strengthens Small Pharma's International Position

GlobeNewswire August 3, 2022

U.S. Patent Grant to Strengthen Small Pharma's DMT Patent Strategy With Injectable Formulation

GlobeNewswire July 26, 2022

George Tziras named Chief Executive Officer of Small Pharma (TSXV:DMT)

Azuka Onwuka July 18, 2022

George Tziras to Succeed Peter Rands as Small Pharma Chief Executive Officer

GlobeNewswire July 18, 2022

Small Pharma Reports Fiscal First Quarter 2023 Highlights

GlobeNewswire July 15, 2022

Small Pharma to Participate in the H.C. Wainwright 1st Annual Mental Health Conference on June 27, 2022

GlobeNewswire June 22, 2022

Small Pharma Reports Highlights for the Fiscal Year Ended February 28, 2022

GlobeNewswire June 9, 2022

Small Pharma To Present at the Jefferies Healthcare Conference in New York City on June 10, 2022

GlobeNewswire May 30, 2022

Small Pharma Shares Business Update Ahead of Annual Financial Results

GlobeNewswire May 25, 2022

Small Pharma to Participate in the PSYCH Symposium: London 2022

GlobeNewswire May 5, 2022

Small Pharma (TSXV:DMT) expands commercial portfolio with DMT-based assets

Caroline Egan  March 10, 2022

Small Pharma Expands Potential of Commercial Portfolio With DMT-Based Psychedelic Assets

GlobeNewswire March 10, 2022

Small Pharma to Participate in the 34th Annual Roth Conference

GlobeNewswire March 9, 2022

Small Pharma (TSXV:DMT) shares analysis of phase 1 data from the combined Phase I/IIa clinical trial of SPL026

Brieanna McCutcheon  February 22, 2022

World's First Clinical Trial for DMT-Assisted Therapy in Major Depressive Disorder Shows Consistent Quality of Psychedelic Response in Phase I

GlobeNewswire February 22, 2022